T. Rowe Price Associates’s Performant Healthcare Inc PHLT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-37,179
| Closed | -$288K | – | 3149 |
|
|
2025
Q3 | $288K | Buy |
37,179
+3,931
| +12% | +$25K | ﹤0.01% | 2623 |
|
|
2025
Q2 | $133K | Buy |
33,248
+3,513
| +12% | +$9.96K | ﹤0.01% | 2834 |
|
|
2025
Q1 | $89K | Buy |
29,735
+840
| +3% | +$2.18K | ﹤0.01% | 2846 |
|
|
2024
Q4 | $88K | Buy |
28,895
+4,927
| +21% | +$16.9K | ﹤0.01% | 2857 |
|
|
2024
Q3 | $90K | Buy |
23,968
+3,664
| +18% | +$12.5K | ﹤0.01% | 2840 |
|
|
2024
Q2 | $59K | Buy |
20,304
+2,289
| +13% | +$6.57K | ﹤0.01% | 2834 |
|
|
2024
Q1 | $53K | Buy |
18,015
+452
| +3% | +$1.29K | ﹤0.01% | 2867 |
|
|
2023
Q4 | $55K | Buy |
17,563
+2,882
| +20% | +$7.55K | ﹤0.01% | 2798 |
|
|
2023
Q3 | $34K | Buy |
14,681
+1,012
| +7% | +$2.57K | ﹤0.01% | 2823 |
|
|
2023
Q2 | $37K | Buy |
+13,669
| New | +$39.6K | ﹤0.01% | 2835 |
|
|
2020
Q3 | – | Sell |
-15,900
| Closed | -$11K | – | 2632 |
|
|
2020
Q2 | $11K | Hold |
15,900
| – | – | ﹤0.01% | 2489 |
|
|
2020
Q1 | $14K | Hold |
15,900
| – | – | ﹤0.01% | 2492 |
|
|
2019
Q4 | $16K | Hold |
15,900
| – | – | ﹤0.01% | 2516 |
|
|
2019
Q3 | $17K | Hold |
15,900
| – | – | ﹤0.01% | 2510 |
|
|
2019
Q2 | $17K | Hold |
15,900
| – | – | ﹤0.01% | 2533 |
|
|
2019
Q1 | $33K | Hold |
15,900
| – | – | ﹤0.01% | 2513 |
|
|
2018
Q4 | $36K | Hold |
15,900
| – | – | ﹤0.01% | 2536 |
|
|
2018
Q3 | $32K | Hold |
15,900
| – | – | ﹤0.01% | 2575 |
|
|
2018
Q2 | $34K | Hold |
15,900
| – | – | ﹤0.01% | 2570 |
|
|
2018
Q1 | $48K | Hold |
15,900
| – | – | ﹤0.01% | 2536 |
|
|
2017
Q4 | $26K | Sell |
15,900
-38,000
| -71% | -$68.5K | ﹤0.01% | 2557 |
|
|
2017
Q3 | $98K | Hold |
53,900
| – | – | ﹤0.01% | 2498 |
|
|
2017
Q2 | $113K | Hold |
53,900
| – | – | ﹤0.01% | 2471 |
|
|
2017
Q1 | $158K | Hold |
53,900
| – | – | ﹤0.01% | 2432 |
|
|
2016
Q4 | $127K | Hold |
53,900
| – | – | ﹤0.01% | 2447 |
|
|
2016
Q3 | $159K | Hold |
53,900
| – | – | ﹤0.01% | 2382 |
|
|
2016
Q2 | $87K | Hold |
53,900
| – | – | ﹤0.01% | 2442 |
|
|
2016
Q1 | $92K | Hold |
53,900
| – | – | ﹤0.01% | 2423 |
|
|
2015
Q4 | $96K | Sell |
53,900
-74,400
| -58% | -$169K | ﹤0.01% | 2430 |
|
|
2015
Q3 | $310K | Buy |
128,300
+4,800
| +4% | +$14K | ﹤0.01% | 2132 |
|
|
2015
Q2 | $400K | Hold |
123,500
| – | – | ﹤0.01% | 2086 |
|
|
2015
Q1 | $420K | Buy |
123,500
+11,000
| +10% | +$55.8K | ﹤0.01% | 2051 |
|
|
2014
Q4 | $748K | Buy |
112,500
+25,000
| +29% | +$183K | ﹤0.01% | 1803 |
|
|
2014
Q3 | $707K | Sell |
87,500
-236,800
| -73% | -$2.28M | ﹤0.01% | 1822 |
|
|
2014
Q2 | $3.27M | Buy |
324,300
+19,300
| +6% | +$176K | ﹤0.01% | 1508 |
|
|
2014
Q1 | $2.76M | Buy |
305,000
+67,900
| +29% | +$590K | ﹤0.01% | 1512 |
|
|
2013
Q4 | $2.44M | Buy |
237,100
+11,600
| +5% | +$117K | ﹤0.01% | 1508 |
|
|
2013
Q3 | $2.46M | Buy |
225,500
+19,600
| +10% | +$214K | ﹤0.01% | 1516 |
|
|
2013
Q2 | $2.39M | Buy |
+205,900
| New | +$2.29M | ﹤0.01% | 1505 |
|
Other funds holding PHLT
T. Rowe Price Associates's PHLT Position: Q4 2025 in Review
T. Rowe Price Associates sold out of Performant Healthcare Inc (PHLT) in Q4 2025, closing a stake of 37,179 shares — an estimated $288K sold.
T. Rowe Price Associates first reported a position in PHLT in Q2 2013 and held it in 39 quarters. The position peaked at $3.27M in Q2 2014. 1 fund tracked by Wall St. Rank holds PHLT as of Q4 2025.
- T. Rowe Price Associates reported no remaining Performant Healthcare Inc position as of Q4 2025 after selling out during the quarter.
- T. Rowe Price Associates sold 37,179 Performant Healthcare Inc shares in Q4 2025, an estimated $288K.
- T. Rowe Price Associates first reported a position in Performant Healthcare Inc in Q2 2013 and held it in 39 quarters.
- T. Rowe Price Associates's Performant Healthcare Inc position peaked at $3.27M in Q2 2014.
- 1 fund tracked by Wall St. Rank held Performant Healthcare Inc as of Q4 2025.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.